MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.aohep.2026.102259

Медицинская библиотека · Annals of hepatology · 2026

Impact of adding statins to non-selective beta-blockers in cirrhosis with portal hypertension: a systematic review and meta-analysis of randomized controlled trials.

Wu Qingping, Yang Yifei, Wu Qi, Wu Yue, Liu Shan

СтатьяПеревод в очереди

Аннотация

INTRODUCTION AND

OBJECTIVES

Despite non-selective beta-blockers (NSBBs), patients with cirrhosis and portal hypertension (PH) remain at substantial risk of death. Statins may improve intrahepatic microcirculation and potentially complement NSBB effects.

MATERIALS AND

METHODS

We searched PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov from inception to October 2025 for randomized controlled trials (RCTs) comparing NSBB-based therapy plus statins versus NSBB-based therapy alone. Rare events were synthesized using fixed-effect Peto odds ratios; other outcomes were pooled with random-effects models, with prediction intervals (PI) reported. Prespecified subgroup and sensitivity analyses were performed.

RESULTS

Seven RCTs (n = 954) were included. Statin add-on therapy was not clearly associated with fewer PH-related complications, including variceal bleeding (RR = 0.79, P = 0.10), new or worsening ascites (RR = 0.81, P = 0.13), or hepatic encephalopathy (RR = 0.41, P = 0.06). However, it was associated with a lower risk of all-cause mortality (RR = 0.46, 95% CI: 0.32-0.65, 95% PI: 0.28-0.76, P < 0.001, I2 = 0). Adding statins also resulted in greater hepatic venous pressure gradient (HVPG) reductions and a higher proportion of patients achieving a ≥ 20% HVPG decrease. Aches and transaminase elevations occurred more often with statins. In subgroup analyses, the mortality association was observed in Child-Pugh A/B patients.

CONCLUSIONS

In cirrhosis with PH, statin add-on therapy is associated with improved portal hemodynamics and lower all-cause mortality, whereas associations with PH-related complications remain uncertain.

PROSPERO REGISTRATION NUMBER: CRD420251172719.

Для цитирования: Wu Qingping, Yang Yifei, Wu Qi, Wu Yue, Liu Shan. Impact of adding statins to non-selective beta-blockers in cirrhosis with portal hypertension: a systematic review and meta-analysis of randomized controlled trials.. Annals of hepatology. 2026. DOI: 10.1016/j.aohep.2026.102259.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.